SCHEMBL6497226

SCHEMBL6497226

CCc1ccc(C2=C(C(=O)Nc3ccc(NCCc4csc(N)n4)nc3)CCCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.40
LMNA P02545 2/20 0.40
POLB P06746 3/20 0.36
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
RXFP1 Q9HBX9 1/20 0.35
MAPT P10636 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
HSD17B10 Q99714 2/20 0.34
MAPK1 P28482 1/20 0.34
DGAT1 O75907 1/20 0.33
LCK P06239 1/20 0.33
CSF1R P07333 1/20 0.33
KDM1A O60341 1/20 0.33
ADRB3 P13945 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499502 0.93 KDM1A (0.40) TP53LMNANPC1RAB9AMAPT
SCHEMBL6502201 0.90 TP53 (0.47) TP53LMNAPOLBNPC1RAB9A
SCHEMBL6488453 0.89 TP53 (0.42) TP53LMNAPOLBMAPTSMN1; SMN2
SCHEMBL6490167 0.86 DGAT1 (0.35) TP53POLBNPC1RAB9AMAPT
SCHEMBL6496990 0.85 RAB9A (0.37) TP53LMNAPOLBNPC1RAB9A
SCHEMBL6487761 0.83 RAB9A (0.45) TP53LMNANPC1RAB9AMAPT
SCHEMBL6492522 0.82 SMN1; SMN2 (0.47) TP53LMNAPOLBNPC1RAB9A
SCHEMBL6492282 0.82 NPC1 (0.41) TP53LMNAPOLBNPC1RAB9A
SCHEMBL6489500 0.79 TP53 (0.49) TP53LMNAPOLBMAPTSMN1; SMN2
SCHEMBL6491525 0.78 ALDH1A1 (0.38) TP53POLBNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 TP53 3031/4885LMNA 629/4885POLB 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.